Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomes
BackgroundAdoptive therapy with umbilical cord blood (UCB) T-regulatory (Treg) cells can prevent graft vs. host disease (GVHD). We hypothesize that UCB Tregs can treat GVHD and synergize with ruxolitinib, Jak2 inhibitor, to improve outcomes.MethodsUCB Treg potency and efficacy was examined using cel...
Saved in:
| Main Authors: | Ke Zeng, Hongbing Ma, Meixian Huang, Mi-Ae Lyu, Tara Sadeghi, Christopher R. Flowers, Simrit Parmar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Transplantation |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/frtra.2024.1448650/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Low dose ATG-Fresenius for GVHD prophylaxis: a comparative study with ATG-Thymoglobulin
by: Itai Falicovich, et al.
Published: (2025-01-01) -
Acute graft versus host disease postliver transplant with mucocutaneous manifestations and pancytopenia: Remission with Janus kinase inhibitor
by: Roy Mendoza, BS, et al.
Published: (2025-08-01) -
Case Report: Successful treatment of steroid- and ruxolitinib-refractory gastrointestinal acute graft-versus-Host disease with anti-thymocyte globulin
by: Lulu Zhang, et al.
Published: (2025-07-01) -
Melanoma during Ruxolitinib Treatment for Myelofibrosis
by: Lingzhi Zhong, et al.
Published: (2025-07-01) -
JAK2 Inhibitors and Emerging Therapies in Graft-Versus-Host Disease: Current Perspectives and Future Directions
by: Behzad Amoozgar, et al.
Published: (2025-06-01)